menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Evolving Gene Therapy: A Deep Dive into 3rd-Generation Lentiviral Vectors

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Sponsored by

  • Overview

    Third-generation lentiviral vectors were developed to improve upon safety measures and mitigate the risks of toxicity and replication that are typically associated with first- and second-generation therapies. These advancements may help enhance the functionality and utility of third-generation lentiviral vectors in various gene therapy applications. Learn more about the development, efficacy, and safety of third-generation lentiviral vectors with Dr. Matt Birnholz and Dr. Donald Kohn, Distinguished Professor at the University of California, Los Angeles.

    This non-certified educational series is produced and controlled by ReachMD, and is intended for healthcare professionals only. 

Facebook Comments

Recommended
Details
Presenters
Comments
  • Sponsored by

  • Overview

    Third-generation lentiviral vectors were developed to improve upon safety measures and mitigate the risks of toxicity and replication that are typically associated with first- and second-generation therapies. These advancements may help enhance the functionality and utility of third-generation lentiviral vectors in various gene therapy applications. Learn more about the development, efficacy, and safety of third-generation lentiviral vectors with Dr. Matt Birnholz and Dr. Donald Kohn, Distinguished Professor at the University of California, Los Angeles.

    This non-certified educational series is produced and controlled by ReachMD, and is intended for healthcare professionals only. 

Facebook Comments

Schedule30 May 2024